- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03619187
An Interventional Study to Evaluate the Effect of Ivabradine on Exercise Capacity in Heart Transplant Recipients
A Phase 3, Open-label, Multicenter Study to Evaluate the Effect of Ivabradine on Exercise Capacity in Heart Transplant Recipients With Elevated Resting Heart Rate
Study Overview
Status
Intervention / Treatment
Detailed Description
The primary goal of this study is to assess the impact of ivabradine on cardiopulmonary exercise capacity in heart transplant recipients with elevated resting heart rate (HR).
Exercise capacity will be assessed by the determination of the peak oxygen consumption (pVO2) during standard cardiopulmonary exercise test before and after the treatment period with ivabradine. The secondary goal is to determine HR reduction with ivabradine in the patient population.
Study Type
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject has provided informed consent/assent prior to initiation of any study-specific activities/procedures
- Male or female, ≥ 18 to ≤ 70 years of age at signing of informed consent
- History of heart transplantation within 1 to 4 years from screening
- Sinus rhythm and elevated resting HR > 95 bpm at screening (ECG)
- Able to perform exercise testing as required per protocol, per the investigator, at time of screening
- Peak VO2 < 70% of the predicted normal value for age and gender with respiratory exchange ratio (RER) ≥ 1.05, from a CPET conducted during screening
Exclusion Criteria:
- Participation in a cardiac rehabilitation program during the study period
- Treatment for heart transplant rejection within the previous 3 months before screening
- Severe allograft vasculopathy limiting the tolerance of CPET at time of screening
- During CPET at screening, significant adverse finding (eg, exercise-induced early ischemic changes, abnormal blood pressure response, unexpected arrhythmia or other serious finding) that precludes safe participation in the study, per investigator
- Sick sinus syndrome, sinoatrial block and/or third degree atrioventricular block, unless a functioning demand pacemaker is present, or pacemaker dependency at screening
- Resting systolic blood pressure >160 mmHg or <100 mmHg, or diastolic blood pressure >90 mmHg at screening
- History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion
- Presence of clinically meaningful acute or chronic infection, per investigator, at screening
- Major medical event or procedure (as determined by investigator) within 3 months prior to screening
- Previously received ivabradine after heart transplantation (prior to the participation in this study)
- Subjects taking QT prolonging medicinal products for cardiovascular (eg, but not limited to, quinidine, disopyramide, bepridil, sotalol, ibutilide) or non-cardiovascular disease (eg, but not limited to, pimozide, ziprasidone, sertindole, mefloquine, halofantrine, pentamidine, cisapride, intravenous (IV) erythromycin)
- Subjects should not be receiving beta-blockers, diltiazem, or verapamil for at least 7 days before screening
- Subjects exposed to a strong Cytochrome P450 3A4 (CYP3A4) inhibitor (examples of strong CYP3A4 inhibitors include; azole antifungals [eg, itraconazole], macrolide antibiotics [eg, clarithromycin, telithromycin], human immunodeficiency virus protease inhibitors, [eg, nelfinavir], and nefazodone]) within 14 days prior to screening, or to a strong CYP3A4 inducer (examples of CYP3A4 inducers include; St. John's wort, rifampicin, barbiturates, and phenytoin) within 28 days prior to screening
- Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(ies). Other investigational procedures while participating in this study are excluded.
- Hemoglobin < 8 g/dL at screening (or within 3 months prior to screening if no clinically meaningful event, as determined by the investigator, has occurred in that period) and not expected to receive blood transfusion during the study
- Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 (by the Modification of Diet in Renal Disease [MDRD] equation) at screening (or within 3 months prior to screening)
- Subject has known sensitivity to any of the products to be administered during dosing
- Female subject is pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment and for an additional 2 weeks after the last dose of investigational product
- Female subjects of childbearing potential unwilling to use 1 highly effective method of contraception during treatment and for an additional 2 weeks after the last dose of investigational product. Refer to Section 12.5 for additional contraceptive information
- Female subjects of childbearing potential with a positive pregnancy test assessed at screening by a serum pregnancy test
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single Arm
Study Product
|
Ivabradine will be provided in bottles (60 tablets per bottle) labeled ivabradine 5 mg and ivabradine 7.5 mg.
The 2.5 mg dose of ivabradine will be achieved by subjects splitting the 5 mg tablets into equal halves.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
pVO2
Time Frame: Week 16
|
To evaluate the effect of treatment with ivabradine on exercise capacity as measured by peak oxygen consumption (pVO2)
|
Week 16
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Resting Heart Rate
Time Frame: Week 16
|
To evaluate the effect of treatment with ivabradine on resting heart rate (HR)
|
Week 16
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 20180037
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Transplantation, Elevated Resting Heart Rate
-
Florida State UniversityCompletedHeart Rate Variability | Appetite | Resting Metabolic RateUnited States
-
Universiti Tunku Abdul RahmanCompletedPrehypertension | Blood Pressure | Resting Heart RateMalaysia
-
Philips Clinical & Medical Affairs GlobalNot yet recruitingHeart Rate | Respiration Rate
-
ContinUse Biometrics Ltd.CompletedHeart Rate | Respiratory RateIsrael
-
Izmir Katip Celebi UniversityCompletedExercise | Pulmonary Rehabilitation | COPD | Resting Heart Rate
-
University Hospital Southampton NHS Foundation...University of SouthamptonCompletedExercise | Heart Rate | Respiratory RateUnited Kingdom
-
KK Women's and Children's HospitalRenew GroupCompletedHeart Rate | Respiratory Rate | Vital SignSingapore
-
KK Women's and Children's HospitalRenew GroupActive, not recruitingHeart Rate | Respiratory Rate | Vital SignSingapore
-
University Health Network, TorontoCompletedVital Signs Monitoring | Blood Pressure, Heart Rate, Respiratory Rate, Heart Rate Variability, Stress Index, Vital Signs MonitoringCanada
-
Arizona State UniversityHonorHealth Research InstituteCompletedStress | Psychological Distress | Hematopoietic Stem Cell Transplantation | Mood | Emotion Regulation | Heart Rate Variability | Communication Research | Bone Marrow Transplant | Autonomic Nervous System | NarrativeUnited States
Clinical Trials on Ivabradine
-
Assistance Publique - Hôpitaux de ParisRecruiting
-
Asan Medical CenterInstitut de Recherches Internationales ServierCompletedHealthy IndividualKorea, Republic of
-
University of California, San DiegoAmgenCompletedPostural Orthostatic Tachycardia SyndromeUnited States
-
Institut de Recherches Internationales ServierCompleted
-
Institut de Recherches Internationales ServierCompletedCoronary Disease | Ventricular Dysfunction, LeftUnited Kingdom
-
Medical University of WarsawUnknown
-
Qian gengRecruiting
-
Institut de Recherches Internationales ServierCompletedHeart Failure, CongestiveItaly
-
Tel-Aviv Sourasky Medical CenterUnknownPostural Tachycardia Syndrome
-
Kanecia Obie ZimmermanEnrolling by invitationLong COVID | Long Covid19 | Long Covid-19United States